Filing Flows › Journey Medical (DERM) › Q1 2025
Journey Medical (DERM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Journey Medical (DERM) reported revenue of $13.1M for the first quarter 2025 (Q1 2025), +0.8% from a year earlier and -4% from the quarter before. Operating margin was -25.3%, net loss $4.1M (31.0% of revenue).
Journey Medical, Q1 2025: revenue $13.1M (+0.8% year over year), operating margin -25.3%, net loss $4.1M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.1M | -4% | +0.8% |
| Operating profit | −$3.3M | -249% | — |
| Net earnings | −$4.1M | -368% | — |
| Operating cash flow | −$2.8M | -227% | — |
What changed
Revenue was $13.1M in Q1 2025, up 1% year over year and down 4% from the previous quarter. Qbrexza was the largest line at 39% of revenue. Amzeeq added $345K year over year (up 46%), 317% of the total change. Other / legacy declined 38%.
Operating costs exceeded revenue by $3.3M, an operating margin of -25.3%. Total costs fell 29% while revenue rose 1%. The fastest-growing cost line was SG&A (+26%). The quarter ended with a net loss of $4.1M, after a profit of $1.5M the previous quarter.
Operating cash flow was −$2.8M. Non-cash charges added back $1.3M of share-based compensation.
Questions
What was Journey Medical's revenue in the first quarter 2025?
Journey Medical (DERM) reported revenue of $13.1M for the first quarter 2025 (Q1 2025), +0.8% from a year earlier and -4% from the quarter before.
Was Journey Medical profitable in the first quarter 2025?
Operating loss was $3.3M (-25.3% of revenue) and net loss $4.1M.
Source: Journey Medical 10-Q on SEC EDGAR.